Inapill
Pre-clinicalInapill develops first-in-class small molecules targeting immunometabolism to improve treatments for inflammatory and autoimmune diseases.
Founded
2020
Focus
Small Molecules
About
Inapill develops first-in-class small molecules targeting immunometabolism to improve treatments for inflammatory and autoimmune diseases.
Funding History
1Total raised: $1.5M
Seed$1.5MUndisclosedMay 15, 2022
Company Info
TypePrivate
Founded2020
LocationSan Francisco, United States
StagePre-clinical
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile